Back to top
more

IDEXX Laboratories (IDXX)

(Real Time Quote from BATS)

$417.31 USD

417.31
268,596

-6.34 (-1.50%)

Updated Nov 15, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

by Zacks Equity Research

The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.

Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3

by Zacks Equity Research

Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

A diversified product portfolio and strong Dental business prospects provide Patterson Companies (PDCO) a competitive edge in the MedTech space.

Here's Why You Should Invest in Integer Holdings (ITGR) Stock

by Zacks Equity Research

Integer Holdings (ITGR) is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q4

by Zacks Equity Research

HealthEquity (HQY) witnesses strong HSA member growth in the fourth quarter of fiscal 2019.

Allscripts Partners With Opargo to Boost Practice Management

by Zacks Equity Research

Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.

Stryker Buys Israel-Based OrthoSpace, Strengthens MedSurg

by Zacks Equity Research

Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.

Allscripts Strengthens Strategic Relationship with Pulse8

by Zacks Equity Research

Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.

Here's Why Investors Should Retain McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.

Allscripts to Fortify Middle East Foothold With New Project

by Zacks Equity Research

Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.

Here's Why Investors Should Bet on Cooper Companies (COO) Now

by Zacks Equity Research

Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.

Here's Why Investors Should Bet on Merit Medical (MMSI) Now

by Zacks Equity Research

Merit Medical's (MMSI) upbeat guidance for 2019 is indicative of the company's brighter prospects.

    Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS

    by Zacks Equity Research

    Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.

    Here's Why You Should Invest in AngioDynamics Stock Now

    by Zacks Equity Research

    Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.

    Here's Why Momentum Investors Will Love Idexx Laboratories (IDXX)

    by Zacks Equity Research

    Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

    by Zacks Equity Research

    IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.

    Bright Near-Term Outlook for Medical Instruments Industry

    by Zacks Equity Research

    Growing medical awareness and economic prosperity have been enhancing the uptake of medical instruments in the emerging economies.

    IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View

    by Zacks Equity Research

    IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.

    Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    Idexx (IDXX) delivered earnings and revenue surprises of 8.89% and 0.69%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

    ZBH & IDXX Q4 Earnings on Feb 1: Here are the Key Predictions

    by Zacks Equity Research

    The global medical device space is passing through a rewarding phase for a considerable period of time in terms of research and development (R&D) plus regulatory progress.

    Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?

    by Zacks Equity Research

    IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.

    Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?

    by Zacks Equity Research

    Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Why Is Idexx (IDXX) Down 0.6% Since Last Earnings Report?

    by Zacks Equity Research

    Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Idexx Laboratories (IDXX) Q3 Earnings Top Estimates

    by Zacks Equity Research

    Idexx (IDXX) delivered earnings and revenue surprises of 7.14% and -0.03%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?